Publications by authors named "M Buglione"
Background/objectives: Adenoid Cystic Carcinoma (AdCC) is a rare malignant salivary gland tumor, with high rates of recurrence and distant metastasis. This study aims to stratify patients Relapse-Free Survival (RFS) using a combined model of clinical and radiomic features from preoperative MRI.
Methods: This retrospective study included patients with primary AdCC who underwent surgery and adjuvant radiotherapy.
Domesticated animals are artificially selected to exhibit desirable traits, however not all traits of domesticated animals are the result of deliberate selection. Loss of olfactory capacity in the domesticated pig () is one example. We used whole transcriptome analysis (RNA-Seq) to compare patterns of gene expression in the olfactory mucosa of the pig and two subspecies of wild boar (), and investigate candidate genes that could be responsible for the loss of olfactory capacity.
View Article and Find Full Text PDFArticle Synopsis
- Researchers aimed to create a survival prediction model for patients with stage I Non-Small Cell Lung Cancer (NSCLC) receiving stereotactic body radiation therapy (SBRT), as no such models currently exist.
- They collected clinical data from patients across three institutions to develop and validate this model using Cox regression and artificial neural networks.
- The model identified two prognostic groups based on survival outcomes, showing promise for clinically stratifying SBRT patients, with recommendations for further validation.
Background: In the randomized phase II REGOMA trial, regorafenib showed promising activity in patients with recurrent glioblastoma. We conducted a large, multicenter, prospective, observational study to confirm the REGOMA data in a real-world setting.
Patients And Methods: The major inclusion criteria were histologically confirmed diagnosis of glioblastoma according to the World Health Organization (WHO) 2016 classification and relapse after radiotherapy with concurrent/adjuvant temozolomide treatment, good performance status [Eastern Cooperative Oncology Group performance status (ECOG PS 0-1)] and good liver function.